Jana Hundertmark

Berlin, BE 13353, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model.

Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 03, 2024

Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.

Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.

Journal: Journal of hepatology

Published: February 02, 2023

Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice.

Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice.

Journal: Cell death & disease

Published: January 18, 2023

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.

Journal: International journal of molecular sciences

Published: May 01, 2022

Single Cell RNA Sequencing in NASH.

Single Cell RNA Sequencing in NASH.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: February 25, 2022

Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.

Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.

Journal: Hepatology (Baltimore, Md.)

Published: December 13, 2021

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.

Journal: Frontiers in medicine

Published: June 15, 2021

How effective are nonalcoholic fatty liver disease models for drug discovery?

How effective are nonalcoholic fatty liver disease models for drug discovery?

Journal: Expert opinion on drug discovery

Published: June 12, 2020

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis.

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis.

Journal: Journal of clinical medicine

Published: March 08, 2020

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆.

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆.

Journal: Journal of hepatology

Published: September 11, 2019

Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis.

Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis.

Journal: Cells

Published: May 01, 2019

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.

Journal: Gut

Published: January 27, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026